STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: A completed share issue of USD 26m in the San Francisco-based company Presidio Pharmaceuticals, Inc., Medivir’s (STO:MVIRB) licensing partner for the antiviral compounds alovudine (MIV-310) and PPI-801/802 (MIV-410), will trigger Medivir receiving Series B shares in Presidio.
